Breaking News

AstraZeneca Unit Acquires AlphaCore Pharma

April 3, 2013

Adds early-stage cardiovascular drug

AstraZeneca’s MedImmune unit has acquired AlphaCore Pharma, a privately held U.S. biotechnology company developing a new type of cholesterol medicine. Financial details were not disclosed.
AlphaCore’s lead drug candidate ACP-501, a genetically engineered liver-derived enzyme called LCAT, completed Phase I trials last year. ACP-501 is being developed to help manage cholesterol to reduce the risk of heart attacks and strokes. It could also play a role in a rare, hereditary disorder called familial LCAT deficiency in which the LCAT enzyme is absent.
"As the science in this area continues to evolve, we are committed to exploring unique pathways that could lead to new combination or standalone therapies for patients living with chronic and acute cardiovascular diseases," said MedImmune head Bahija Jallal.

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry